Colon Cancer and Tocotrienols Protective Role…What is the Physiology and What is the Evidence… An Interview with Ammu K. Radhakrishnan PhD, MSc

Posted on by


Peer Reviewed Cancer Study – Mebendazole/Ivermectin; Covid Vax & Heart Damage; Brain Health, Marijuana & Youth; Fatty Liver Heart Attack Linked; Depression & Digital Addiction; Heart Function & CoQ10 and More…

Colon Cancer and the Protective Role of Gamma and Delta Tocotrienols (Vitamin E Components) … What is the Physiology and What is the Evidence

Ammu K. Radhakrishnan PhD, MSc

Food as Medicine Research Strength
Jeffrey Cheah School of Medicine and Health Sciences
Monash University Malaysia, 47500 Bandar Sunway, Malaysia
Ammu.radhakrishnan@monash.edu

Insights into the Anticancer Mechanisms Modulated
by Gamma and Delta Tocotrienols in Colorectal Cancers
Nutr Rev. 2025 Mar 1;83(3):e1295-e1310.” (6/2026)

Interview Summary…

In this interview, Dr. Ammu K. Radhakrishnan, Professor of Immunology at Monash University Malaysia, discusses her research on the anticancer potential of gamma- and delta-tocotrienols, lesser-known members of the vitamin E family, particularly in relation to colorectal cancer prevention and adjunctive therapy. Unlike the more commonly recognized alpha-tocopherol form of vitamin E, tocotrienols possess an unsaturated side chain that may allow them to interact differently with cell membranes and biological pathways, potentially explaining their stronger anticancer effects seen in experimental models. Dr. Radhakrishnan explains that gamma- and delta-tocotrienols demonstrate multiple cancer-modulating mechanisms, including inhibition of cancer cell proliferation, induction of apoptosis (programmed cancer cell death), promotion of cell-cycle arrest, suppression of angiogenesis (tumor blood vessel formation), inhibition of metastasis, possible effects on telomerase activity, and modulation of inflammatory and immune pathways. Dr. Radhakrishnan and colleague’s review paper “Insights into the Anticancer Mechanisms Modulated by Gamma and Delta Tocotrienols in Colorectal Cancers,” analyzed research from the past two decades, including 26 cell studies, 9 animal studies, 2 randomized clinical trials, and 1 scoping review. The accumulated evidence suggests these compounds may influence key cancer pathways such as Wnt/beta-catenin signaling, tumor-stromal interactions, inflammatory signaling, and noncoding RNA regulation, making tocotrienols of interests as supportive compounds in cancer research rather than standalone treatments.

Dr. Radhakrishnan emphasizes that tocotrienols appear especially promising because they act through multiple biological targets rather than a single pathway, which is important given the complexity of colorectal cancer, treatment resistance, recurrence, and cancer stem cell behavior. Some research suggests possible effects on the gut microbiome, with delta-tocotrienols shown in animal studies to increase potentially beneficial bacteria such as Lactococcus and Bacteroides while reducing inflammatory changes associated with carcinogenesis. (Note: While non-toxigenic strains of Bacteroides fragilis (NTBF) are normal, harmless, and beneficial parts of the human gut microbiome, Enterotoxigenic Bacteroides fragilis (ETBF) carry a specific gene (bft) that produces a harmful pro-inflammatory protein known as Bacteroides fragilis toxin (BFT) that can increase cancer risk). Human clinical evidence remains preliminary but encouraging: an early trial combining delta-tocotrienol with FOLFOXIRI chemotherapy suggested safety and a possible neuroprotective effect, although definitive effectiveness has not yet been proven.

Rich dietary sources of tocotrienols include annatto oil, palm oil, and rice bran oil, with the natural balance of vitamin E compounds varies greatly among foods. Refining, oxidation, storage, and high-temperature processing can reduce tocotrienol content. Dr. Radhakrishnan notes for the treatment of cancer and other acute conditions a dose of tocotrienols between 200-400 mg of a tocotrienol rich fraction (TRF) in a dietary supplement (75% tocotienols/25% tocopherols) can be practically obtained. These doses are not possible through dietary means or taking the free form oils (rice bran, annatto seed or palm oils). Dr. Radhakrishnan concludes that while gamma- and delta-tocotrienols (especially delta) show strong preclinical anticancer potential, they should currently be viewed as investigational adjunctive agents rather than solo cancer treatments. Further research is needed to determine optimal dosing, absorption, biomarkers, and clinical effectiveness, but their broad mechanisms, favorable safety profile, and ability to influence cancer biology provide a strong rationale for future human trials. (AI summary of this print interview reviewed and edited by Kirk Hamilton PA)

(Kirk Hamilton PA’s print interview with Dr. Ammu Radhakrishnan several weeks prior to the above video interview regarding the paper: Insights into the Anticancer Mechanisms Modulated by Gamma and Delta Tocotrienols in Colorectal Cancers )

Kirk Hamilton: Can you please share with me your educational background and current position?

Ammu K. Radhakrishnan: I am a Professor of Immunology at Monash University Malaysia. My academic training includes a BSc (Hons) and MSc from the University of Malaya, and a PhD in Immunology from the University of Cambridge. My research focuses on cancer immunology, cancer immunotherapy, nutritional immunology, natural product therapeutics, and immune modulation.

KH: What got you interested in studying tocotrienols in the first place and why the special interest for colon cancer?

AKR: My long-standing interest is in how natural bioactive compounds can modulate immune and cancer pathways. Tocotrienols are particularly interesting because they are lesser-known vitamin E compounds with antioxidant, anti-inflammatory, and anticancer properties. Colon cancer is important because it remains common worldwide, treatment resistance is a major challenge, and diet, inflammation, microbiota, and tumor microenvironment all influence disease progression.

KH: Can you describe what are tocotrienols, the different forms of tocotrienols and how they “balance” tocopherols in the vitamin E molecule?

AKR: Vitamin E has two main families: tocopherols and tocotrienols. Each has four isoforms: alpha, beta, gamma, and delta. Tocopherols have a saturated side chain, while tocotrienols have an unsaturated side chain with three double bonds. This structural difference may help tocotrienols enter tissues and membranes differently and may explain some of their stronger biological effects. To date, alpha-tocopherol is the officially recognized essential vitamin E form. However, gamma- and delta-tocotrienols appear to have stronger anticancer activity than alpha-tocopherol in several experimental systems. Interestingly, alpha-tocopherol may sometimes reduce delta-tocotrienol uptake and weaken its anticancer effect, so “balance” here means the relative proportions of tocopherols and tocotrienols can influence biological activity.

KH: In “whole foods” are tocopherols and tocotrienols in a particular balance/ratios? Does this balance very from food to food? And how does food processing alter tocotrienol content and balance in foods?

AKR: There is no single natural ratio of tocopherols to tocotrienols in foods. The balance varies considerably depending on the source. For example, olive and sunflower oils are dominated by tocopherols, whereas palm oil, rice bran oil, and annatto are much richer in tocotrienols. Food processing can significantly affect this balance because tocotrienols are sensitive to heat, oxygen, and refining procedures. Extensive refining, prolonged storage, and repeated high-temperature cooking can reduce tocotrienol content and alter the natural vitamin E profile. From a health perspective, this is important because emerging evidence suggests that the different forms of vitamin E may interact biologically, and some studies indicate that high levels of α-tocopherol may reduce the cellular uptake of certain tocotrienols. Therefore, obtaining vitamin E from minimally processed foods may provide a broader spectrum of bioactive compounds than relying on a single isolated form.

KH: Can you tell us about your study and the basic results?

AKR: Our paper was a narrative review of evidence from the past two decades on gamma- and delta-tocotrienols in colorectal cancer. We identified 38 relevant studies: 26 cell-based studies, 9 animal studies, 2 randomized clinical trials, and 1 scoping review. Overall, the evidence suggests that gamma- and delta-tocotrienols can inhibit colorectal cancer cell proliferation, induce apoptosis and cell-cycle arrest, suppress metastasis and angiogenesis, affect telomerase, interact with immune and inflammatory pathways, and sometimes synergize with established anticancer agents.

KH: You list multiple mechanisms of how tocotrienols might work as adjunctive therapies in colon cancer treatment; cell apoptosis, cell cycle arrest, telomerase inhibition, suppression of metastasis and angiogenesis, synergize with anti-cancer agents, modify immune function, tumor-stromal interaction and regulating noncoding RNAs, etc..Can you specifically comment on their role in suppressing cancer stem cells and how they might alter the gut flora?

AKR: Cancer stem cells are important because they may drive recurrence, metastasis, and therapy resistance. However, the evidence of cancer stem cells in colorectal cancer is limited. In colorectal cancer, CD133 is one commonly discussed cancer stem cell biomarker. The direct evidence for tocotrienols regulating CD133 in colon cancer is still limited, so this remains an important research gap. However, gamma-tocotrienol has been shown to suppress cancer stem cell markers in other cancers, which gives us a rationale to study this more deeply in colorectal cancer.

For gut flora, the evidence is more direct but still preclinical. For instance, delta-tocotrienol and its metabolite have been reported in animal models to modulate gut microbiota, including increasing potentially beneficial bacteria such as Lactococcus and Bacteroides, while reducing inflammatory changes linked to carcinogenesis. This is exciting because colon cancer is strongly influenced by the gut environment.

KH: There were two human trials that you reviewed can you tell us anything positive about tocotrienol’s use from those two studies?

AKR: A phase II trial of delta-tocotrienol with FOLFOXIRI showed a hazard ratio of 0.70 for delaying serious adverse events, although this did not reach statistical significance. So, the positive message is safety and a signal of possible supportive benefit, but not yet definitive efficacy.

KH: What were the “therapeutic” doses of the tocotrienols used (gamma and delta)?

AKR: In the clinical trials reviewed, the focus was delta-tocotrienols. The review summarized the clinical trial outcomes, but for several experimental studies the exact dose was not available in the table. Furthermore, the human trials mentioned in this review paper used delta-tocotrienol as an adjunct, not gamma-tocotrienol. There is no doubt that more dose-finding and biodistribution studies are needed before we can define an optimal therapeutic dose.

In cell-based studies, the effective concentration varied widely, often in the micromolar range. For example, delta-tocotrienol showed activity around 14–20 micromolar in some colorectal cancer cell lines, while gamma-tocotrienol activity varied depending on the cell line.

KH: What foods sources are rich in tocotrienols?

AKR: Tocotrienols are found mainly in certain plant oils. Rich sources include palm oil, annatto seed oil, and rice bran oil. They are also present in smaller amounts in some cereal grains and seeds.

KH: We hear of negative health effects of refined palm oil. How do we use palm oil safely in the diet and find it in whole foods?

AKR: Palm oil is often discussed in a negative context, but it is important to distinguish between highly refined palm oil used in some processed foods and the natural oil derived from the palm fruit. Palm oil is one of the richest natural dietary sources of tocotrienols, particularly gamma- and alpha-tocotrienols. Palm oil also contains tocopherols, and carotenoids.

From a scientific perspective, palm oil has made an important contribution to tocotrienol research by providing a naturally abundant source of these compounds. Many of the anticancer, anti-inflammatory, and antioxidant effects reported in the literature have been studied using tocotrienols originally derived from palm oil. As with any dietary fat, moderation and appropriate use are important. When consumed as part of a balanced diet, palm oil can contribute valuable bioactive nutrients, particularly tocotrienols, which are difficult to obtain in significant amounts from many other foods.

KH: How safe are tocotrienols? Any concerns?

AKR: Overall, tocotrienols appear to be well tolerated in the studies reviewed, including the early human colorectal cancer trials, especially compared with many cytotoxic cancer therapies. However, the main concerns are that clinical data remain limited, optimal dosing is not established, and patients should not use tocotrienols as a replacement for standard cancer treatment. They should be considered investigational adjuncts until stronger clinical evidence is available.

KH: Were there any surprises or unexpected results from your study?

AKR: One interesting finding was how broad the mechanisms appeared to be. Tocotrienols were not acting through just one pathway. They influenced proliferation, apoptosis, inflammation, Wnt/beta-catenin signaling, angiogenesis, telomerase-related pathways, and the tumor microenvironment. Another striking observation was that delta-tocotrienols showed minimal impact on normal colon mucosal cells in one study while affecting cancer cells.

KH: What result from this study gave you the most satisfaction, excitement or hope for potential public benefit?

AKR: The most hopeful aspect is the possibility of using tocotrienols as adjunctive agents, i.e., as compounds that may improve cancer control or reduce treatment burden when combined with standard therapies. The early clinical data are not definitive, but the safety signal and the multiple anticancer mechanisms give a strong rationale for further translational and clinical research.

KH: Is there any other comments you would like to make on this important subject?

AKR: I would emphasize that tocotrienols are promising but still require rigorous clinical validation. Although, gamma- and delta-tocotrienols show strong anticancer potential in colorectal cancer in the pre-clinical studies, and there are early clinical data that suggest they are worth studying further. However, the goal is not to promote them as a cure, but to understand whether they can be safely developed as supportive or adjunctive agents in colorectal cancer care. We need well-designed human trials, pharmacokinetic studies, and biomarker-driven research before making clinical recommendations. Tocotrienols are promising, but the science must lead the translation.

KH: Thank you Dr. Radhakrishnan for your time and beneficial research.

For a further review of the role of tocotrienols in health and disease as well as the science and history behind tocotrienols, especially delta-tocotrienols, go to Barrietan.com.

Share

($5.00/month or $50/year would be appreciated for this free weekly publication)

Highlights…

COVID 19 – VACCINE – MYOCARDITIS – HEART DAMAGE – DENIAL – Dead athletes, concealed lab files, and a world blind to the COVID19 vaccine debacle, Peter McCullough. MD, The McCullough Report, Jun 1, 2026. ( Note: An important listen for reviewing the data of how the negative health effects of the Covid 19 vaccine have been ignored and continue to be promoted by mainstream health authorities)
1) Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents.
2) Serial Changes in Troponin I in COVID-19 Vaccine-Associated Myocarditis.
3) Rational harm-benefit assessments by age group are required for continued COVID-19 vaccination.
4) Autopsy findings in cases of fatal COVID‐19 vaccine‐induced myocarditis
5) Role of the antigen presentation process in the immunization mechanism of the genetic vaccines against COVID-19 and the need for biodistribution evaluations.
6) Excess Cardiopulmonary Arrest and Mortality after COVID-19 Vaccination in King County, Washington.

HYDROXYCHLOROQUINE – DIDIER RAOULT, MD – ANTIVIRAL – SARS-CoV-2 Professor Didier Raoult & Hydroxychloroquine. Nicholas Hulscher’s exposition of HCQ’s anti-viral property reminded me of the seminal work of the great French microbiologist and master of repurposed drug therapies. John Leake, Focal Points, May 31, 2026.

IVERMECTIN – CANCER TREATMENT – IVERMECTIN – MEBENDAZOLE – The Fascinating Properties of Ivermectin. Publication of new paper on the anti-cancer properties of ivermectin prompted me to review the wondrous story of this wonder drug. John Leake, Focal Points, May 30, 2026.
1) Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. Anticancer Research. June 2026, 46 (6) 3243-3255. “…Conclusion: In this prospective real-world cohort of patients with cancer, ivermectin and mebendazole were associated with high rates of self-reported clinical benefit and favorable tolerability. These findings are hypothesis-generating and support the need for randomized controlled trials…” PDF – Full Article Comment: This is peer-reviewed in a well established cancer journal (Anticancer Research). Excellent to share with colleagues, personal physician and oncologist. Share the PDF and Pub Med links. This is a landmark study that could stimulate change on how oncology is practiced. Share it. “…The distribution of average daily dosing was asfollows: one capsule per day in 54 participants (44.3%), two capsules per day in 34 (27.9%), three capsules per day in 14 (11.5%), and four capsules per day in 15 (12.3%). Other or variable dosing was reported by five participants (4.1%)…” Each capsule was compounded Ivermectin 25 mg / Mebendazole 250 mg.

NEAR DEATH EXPERIENCE – I Interviewed People Who Came Back From Death. They All Had a Similar Message. Coming back from death is a real life-changer. Makai Elías Calles, Epoch Times, May 30, 2026. Watch “Final Hours: Is Death Really the End?”
1) Long-term transformational effects of near-death experiences

Nutrition, Prevention and Integrative Medicine…

ALPHA-GAL SYNDROME – TICK – MEAT ALLERGY – Study Reports 96% Remission Rate of Alpha-Gal Syndrome with Novel Desensitization Technique. With nearly 500,000 Americans now affected by tick-induced meat allergy, a peer-reviewed study reports almost unbelievable results using Soliman Auricular Allergy Treatment (SAAT). Nicolas Hulscher, MPH, Focal Points. May 29, 2026.
1) Successful Treatment for Alpha Gal Mammal Product Allergy Using Auricular Acupuncture: A Case Series. “…The SAAT method showed effectiveness in the large majority of patients. No adverse reactions were noted as a result of auricular acupuncture…”

ANXIETY – DEPRESSION – DIGITAL ADDICTION – Digital Despair: How Social Media Fuels Teen Anxiety and Overmedication. More teens are experiencing anxiety and depression, taking medication, and struggling with the fallout of drugs—problems that can carry into adulthood. Amy Denney, Epoch Times, April 09, 2025.
1) Kids Turn to TikTok for Mental Health Diagnoses. What Should Schools Know? By Alyson Klein Education Week, March 25, 2024.
2) Scrolling through adolescence: a systematic review of the impact of TikTok on adolescent mental health.
3) Children and teens with anxiety or depression in United States.
4) Trends in Office-Based Anxiety Treatment Among US Children, Youth, and Young Adults: 2006–2018.
5) Nationwide trends in diagnosed sedative, hypnotic or anxiolytic use disorders in adolescents and young adults enrolled in Medicaid: 2001–2019.
6) Drug overdose risk with benzodiazepine treatment in young adults: Comparative analysis in privately and publicly insured individuals.”…Conclusions: Among young adults in the United States, initiating benzodiazepine treatment for anxiety and depression, alone or simultaneously with selective-serotonin reuptake inhibitors (SSRI), appears to have an increased risk of medically treated drug overdose compared with SSRI treatment alone. These associations were observed in publicly and privately insured individuals…”

BRAIN HEALTH – MARIJUANA – YOUTH – Not Just Getting High: How Weed Changes Your Brain’s Future. David Perlmutter, MD, April 29, 2026. “…First, this isn’t about fear or judgment, it’s about understanding how the brain works. The developing brain is uniquely sensitive to environmental inputs. The endocannabinoid system, which THC directly influences, plays a key role in guiding brain development, helping neurons connect, communicate, and mature. Disrupting that system during a critical window can have lasting, if not permanent consequences.

Second, timing matters. Delaying cannabis use, even by a few years, may significantly reduce its impact on long-term cognitive function. Early exposure carries greater risk because it intersects with a period of rapid and essential brain development. And to be sure, this is not to say that smoking weed later in life is without risk.

Third, today’s weed is not what it used to be. Modern cannabis products often contain far higher levels of THC than in previous decades, meaning the biological signal to the brain is stronger, and potentially more disruptive…”
1) Longitudinal neurocognitive trajectories in a large cohort of youth who use cannabis: combining self-report and toxicology.

EBOLA – WHO – Ebola Hype: How the WHO Manufactures Outbreak Stories to Push Future Vaccines. 129 confirmed cases, zero ICU care, 100% fear — McCullough breaks down why the latest WHO “emergency” is a sanitation problem, not a shot shortage. Peter A. McCullough, MD, MPH, Focal Points, Jun 03, 2026.

DIABETES – HEART DISEASE – HEALTH HABITS – Study Links Eight Heart-Healthy Habits to Lower Diabetes Risk in Postmenopausal Women. Healthier diet, exercise, and nonsmoking were among habits associated with lower risk of diabetes.
1. Life’s Essential 8 and Risk of Type 2 Diabetes in the Women’s Health Initiative.
“…This study showed that higher LE8 scores were significantly associated with a reduced risk of incident T2D in postmenopausal women…”

HEART FUNCTION – COQ10 – LOVASTATIN – Lovastatin decreases coenzyme Q levels in humans. PubMed “…Oral administration of CoQ10 increased blood levels of CoQ10 and was generally accompanied by an improvement in cardiac function. Although a successful drug, lovastatin does have side effects, particularly including liver dysfunction, which presumably can be caused by the lovastatin-induced deficiency of CoQ10…”

HEPATIC STEATOSIS – CARDIOVASCULAR RISK – CORONARY ARTERY PLAQUE – Fatty liver disease linked to higher risk of heart attacks. News Medical Life Sciences, Mass General Brigham, May 20 2026.
1) Hepatic Steatosis Is Associated With Increased Cardiovascular Risk Through Adverse Coronary Plaque Composition. “…Conclusions: Hepatic steatosis was associated with greater noncalcified plaque burden and increased risk of major adverse cardiovascular events, with noncalcified plaque burden accounting for a portion of this association, suggesting a link between hepatic steatosis and vulnerable coronary atherosclerosis…”

MUSCULOSKELETAL DISORDERS – PEPTIDES -BPC-157 — A 2025 systematic review of 36 studies confirmed consistent improvement in muscle, tendon, ligament, and bone healing. A key mechanism is stimulating the growth of new blood vessels in tissues which help stimulate repair of those tissues.
1) Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.”…Conclusion: This systematic review of level IV and level V studies suggests that BPC-157 shows promise for promoting recovery from musculoskeletal injuries. Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety…”

($5.00/month or $50/year would be appreciated for this free weekly publication)

Cancer…

BREAST CANCER – FEBENDAZOLE – CASTOR OIL – Topical Castor Oil and Fenbendazole Cream – 52 year old woman in ROMANIA with Stage 4 Breast Cancer reports after 3 months…Cancer markers improving! William Makis, MD, Covid Intel, May 30, 2026.

BREAST CANCER – IVERMECTIN – MEBENDAZOLE – 48 year old TEXAS woman with Early Stage Breast Cancer reports after 12 months – No Evidence of disease but Oncologist is not happy with the result! William Makis, MD, Covid Intel, May 25, 2026.

BREAST CANCER – IVERMECTIN – MEBENDAZOLE – CHLORINE DIOXIDE – 62 year old Texas Woman with Stage 3 Breast Cancer Reports after 5 months: tumors shrinking, no conventional treatment! William Makis, Covid Intel, May 25, 2026.

CANCER – METABOLIC DISEASE – FATTY ACID OXIDATION – Does the fact that cancers may depend on fatty acid oxidation negate the metabolic theory of cancer (Warburg Effect). Paul Marik, MD, The importance of the Metabolic Trap, Cancer & Metabolic Healing, May 31, 2026. “…Cancer is a metabolically active systems disease…” Excellent diagrams of “The Real Metabolic Trap: Multi-Axis Metabolic Pressure in Cancer” Illustrating – Glucose Metabolism – Berberine, Metformin; Mitochondrial Function – Doxycycline, Ivermectin; Cytoskeleton/Mitosis – Mebendazole; Adrenergic Signaling – Propranolol; Circadian/Oxidative Stress – Melatonin.

LEUKEMIA – IVERMECTIN – FENBENDAZOLE – 45 year old ROMANIAN woman with AML Acute Myeloid Leukemia reports after 6 months…blasts decrease 36% to16% to 8%.. William Makis, MD, Covid Inel, Jun 03, 2026.

PROSTATE – IVERMECTIN – FENBENDAZOLE – 66 year old Texas Man with Stage 4 Prostate Cancer to bones reports after 8 months: healed bone metastases! No chemo, no hormones… William Makis, MD, Covid Intel, Jun 02, 2026.

CANCER – WARBURG EFECT- FATTY ACID OXIDATION – Warburg and Fatty Acid Oxidation: A Clearer Understanding. Paul Mark, Cancer & Metabolic Healing. Jun 02, 2026.

PANCREATIC CANCER – LIVER – IVERMECTIN – FENBENDAZOLE – 62 year old Australian man with Stage 4 Pancreatic Cancer to liver reports after 3 months: improving…No chemo…Oncologist amazed by results! William Makis, Covid Intel, May 30, 2026.

PROSTATE CANCER – IVERMECTIN – FENBENDAZOLE – 84 year old Florida Man with Stage 4 Prostate Cancer Reports after 4 months: PSA 425 to 2.2, ALK Phos 3655 to 209! William Makis, MD, Covid Intel, May 29, 2026.

RECTAL CANCER – IVERMECTIN – FENBENDAZOLE – 65 year old Washington man with Stage 2 Rectal Cancer responds after 6 months – became eligible for surgery, which was a success! William Makis, MD, Covid Intel, May 30, 2026.

RECTAL CANCER – IVERMECTIN – FENBENDAZOLE – 63 year old California man with Stage 4 Rectal Cancer and 6cm tumor reports after 3 months: incredible response! 6cm tumor gone…William Makis, MD, Covid Intel, May 29, 2026.

($5.00/month or $50/year would be appreciated for this weekly publication)

Covid Syndrome…

COVID 19 – VACCINE – MYOCARDITIS – HEART DAMAGE – DENIAL – Dead athletes, concealed lab files, and a world blind to the COVID19 vaccine debacle, Peter McCullough. MD, The McCullough Report, Jun 1, 2026. ( Note: An important listen for reviewing the data of how the negative health effects of the Covid 19 vaccine have been ignored and continue to be done so by mainstream health authorities)
1) Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents.
2) Serial Changes in Troponin I in COVID-19 Vaccine-Associated Myocarditis.
3) Rational harm-benefit assessments by age group are required for continued COVID-19 vaccination.
4) Autopsy findings in cases of fatal COVID‐19 vaccine‐induced myocarditis
5) Role of the antigen presentation process in the immunization mechanism of the genetic vaccines against COVID-19 and the need for biodistribution evaluations.
6) Excess Cardiopulmonary Arrest and Mortality after COVID-19 Vaccination in King County, Washington.

($5.00/month or $50/year would be appreciated for this free weekly publication)

Societal and World Health…

ENERGY – OIL PRODUCTION – U.S COMPANIES – Why US Oil Companies Are Holding Off on Drilling New Wells. ‘Oil companies are hesitant to make such big investments over what may be a temporary price spike,’ economist Paul Mueller said. Kevin Stocklin, Epoch Times, 5/31/2026

TIENANMEN SQUARE MASSACRE JUNE 4, 1989 – PHOTOS – Never-Before-Seen 1989 Tiananmen Square Massacre Photos. For decades, film rolls containing more than 2,000 photos documenting the 1989 Tiananmen Square democracy movement had been shut inside a metal box, never known to the world. These photos…
China Watch, Epoch Times, June 5, 2026.

Share

($5.00/month or $50/year would be appreciated for this weekly publication)

Dr. Joe Dispenza’s Website – Mind Body Healing

Falun Dafa – Truthfulness, Compassion and Forbearance
Brief Introduction to Falun Dafa
Falun Gong Misconceptions
Books & Recent Writings of Mr. Li Hongzhi
Video & Audio Materials
Take an Online Class

Kirk Hamilton PA-C
Health Associates Medical Group
3301 Alta Arden, Suite 3
Sacramento, CA 95825
(916) 489-4400 (w)
krhammer@surewest.net
www.StayingHealthyToday.Substack.com
www.StayingHealthyToday.com
www.HealthyLivingforBusypeople.com
www.KwikerMedical.com

Staying Healthy Today is a reader-supported publication.
To receive new posts and support my work, consider becoming a free or paid subscriber.

($5.00/month or $50/year would be appreciated for this free weekly publication)